[at noodls] – — Results from Phase 3 VALENCE Study Confirm Efficacy and Safety of All-Oral Sofosbuvir-Based Regimen in Hepatitis C Patients with Genotype 3 Infection — WASHINGTON–(BUSINESS WIRE)–Nov. 2, 2013– Gilead … . . . → Read More: Company Update: Gilead Sciences Inc. (NASDAQ:GILD) – Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients Similar posts: Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review Oil and Natural Gas Stocks: This small U.S.-based energy company has it all Boeing’s Double Top: Will the company continue to soar?